Tracing the Treatment Journey Using Real-World Data Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous...
In DRG Blog/ September, 2019 Select Highlights from EULAR 2018 JAK Inhibitors and Biosimilars The 19th Annual European League Against Rheumatism (EULAR) congress concluded its four-day event on June 16, 2018 in...
In DRG Blog/ July, 2018 More Intravenous Therapies for Psoriatic Arthritis Lessons from the RA market (claims data analysis) The second half of 2017 has seen FDA approvals of two intravenous (IV) therapies, i.e., BMS’s...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Leader, Mentor, Maverick, Friend: Celebrating the Life of Sarah Fuller The DRG family is coming to terms this month with the loss of one of its most beloved and influential leaders. Sarah W. Fuller, who co-founded...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 ITCA-650’s Opportunity in the Type 2 Diabetes Market ITCA-650, a subdermal osmotic implant that provides continuous delivery of exenatide, is being developed by Intarcia Therapeutics for the treatment...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 The Osteoporosis Market is Set to Increase to $9.1 billion in 2026 Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures place a considerable burden...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Stability Swings Back to State-Run Exchanges For health exchanges, stability has swung around the markets like a pendulum. At first, drastic problems with Healthcare.gov affirmed the decision...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Trump and Republicans Lose Big on Election Night President Donald Trump and the Republicans took a beating in the November 2017 elections, and healthcare was at the forefront. Democrats were...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 What’s the Optimal Treatment Sequence for your Oncology Brand? Despite the significant volume of data and insights gleaned from the current explosion in real world data, we should not overlook or underestimate...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Drug Store Consolidation to Prompt Industry Shifts in Patient Strategy Although federal antitrust concerns forced Walgreens to drop plans to acquire fourth-largest retail clinic operator Rite Aid, the drug store giant...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Biosimilars: All You Need is Trust Key stakeholders in the uptake of biosimilars, including manufacturers, regulators, physicians, and patients, all have an important role to play in...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Ferric Citrate: Killing Two Birds with One Stone in CKD? Renal anemia and hyperphosphatemia are both common complications associated with chronic kidney disease (CKD). Phosphate binders are frequently...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Drug Laws Create Animosity Between State Governments and Pharma Shortly after Donald Trump won the White House, one of the more widely accepted concepts he pitched was going after high drug prices. The president...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Merger speculation, vertical integration of pharmacy lives shakeup PBM CVS/Aetna speculation and Anthem’s PBM aspirations point to changes ahead Speculation that CVS Health is making overtures to purchase Aetna has...
In DRG Blog, Digital Innovation, Drug Watch/ November, 2017 Consolidation, shift to value disrupting MedTech at market level The U.S. healthcare ecosystem is responding to the challenges of aging and ailing populations, new legislation and regulation, and shifting market...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ November, 2017 Understanding Crohn's Disease Therapy Switch Patterns in Germany Based on Real-World Evidence Our therapy area experts and data scientists recently completed a study of Crohn’s Disease patient data from Germany...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ October, 2017 How is Real-World Evidence Used in Health Technology Assessment? Real-world evidence, (RWE), also known as observational data, was once the poor relation of experimental research. The clinical community often...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ October, 2017 AI, Amazon & Chatbots, Oh My! Artificial intelligence, machine learning and Internet of Things are relatively new terms to a healthcare industry that is in the process of...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ October, 2017 Using Real World Data to Understand Patient-Level Drivers Underlying Brand Use in RA There continues to be a great deal of buzz around real-world data (RWD). For biopharmaceutical companies raised on conventional market research,...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ October, 2017 Opioid Epidemic Spawns Flurry of PBM Programs to Address Abuse Express Scripts, other major PBMs tighten controls on opioids Abuse and overuse of opioids continues to be a hot topic as lawmakers and healthcare...
In DRG Blog, Digital Innovation, Drug Watch, Market Access/ October, 2017